[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sensitive-skin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sensitive-skin":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,76,100,123],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100652487","dermal-and-ophthalmological-acceptability-assessment-in-sensitive-skin-100652487",false,"NCT07771998","Dermal and Ophthalmological Acceptability Assessment in Sensitive Skin","Evaluation of the Dermal and Ophthalmological Acceptability of Blancy Pro in Subjects With Sensitive Skin","ADOPS","Inclusion Criteria:\n\n* Female participants aged 18 to 60 years.\n* Participants with any skin type, with at least 25% representation of each skin type.\n* Participants with sensitive skin, clinically confirmed by the Stinging Test.\n* Intact skin in the assessment area.\n* Willingness to comply with all study procedures and attend scheduled visits and assessments.\n* Ability to understand, provide written informed consent, and sign the Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women, or women at risk of becoming pregnant during the study.\n* Use of anti-inflammatory, immunosuppressive, or antihistamine medications within 3 weeks prior to screening.\n* Skin marks or conditions in the study area that may interfere with the evaluation of skin reactions, including vascular malformations, scars, excessive hair growth, multiple nevi, or sunburn.\n* History of atopic disease or allergy to cosmetic products.\n* Active skin diseases and\u002For lesions in the assessment area or elsewhere on the body.\n* Immunosuppression due to medication use or active disease.\n* Uncontrolled endocrine disorders.\n* Relevant medical history or current evidence of alcohol or drug abuse.\n* Known history or suspected intolerance to products of the same category as the investigational product.\n* Intense sun exposure within 15 days prior to assessment.\n* Aesthetic or dermatological treatments within 4 weeks prior to assessment.\n* Any other condition that, in the investigator's opinion, may justify exclusion from the study. Reasons for exclusion will be documented in the clinical record.\n* Participants with entropion, ectropion, hordeolum (stye), conjunctivitis, uveitis, or other active ocular diseases at screening.\n* Participants with corneal ulceration, blepharitis, meibomitis, pterygium, trichiasis, distichiasis, or other moderate to severe ocular disorders.\n* Initiation of contact lens use within 1 week prior to screening.\n* Use of ophthalmic products, including eye drops and\u002For ophthalmic ointments, within 3 weeks prior to screening.\n* Any other ocular condition that, in the investigator's opinion, may justify exclusion from the study. Reasons for exclusion will be documented in the clinical record.",true,"FEMALE","18 Years","60 Years",{"count":22,"type":23},33,"ESTIMATED","INTERVENTIONAL",[26],"NA","This is a single-center, single-blind clinical study designed to evaluate the safety of the investigational product through dermatological and ophthalmological clinical assessments. A total of 33 female participants, aged 18 to 60 years, with a clinical diagnosis of sensitive skin confirmed by the Stinging Test, will be enrolled. Safety evaluations will be performed throughout the study period using standardized clinical assessments.",[29],"Sensitive Skin","RECRUITING","2026-08-17",{"date":33,"type":34},"2026-08-19","ACTUAL",{"date":36,"type":34},"2026-07-20",{"date":38,"type":23},"2026-09-03",{"name":40,"class":41},"Brainfarma Industria Química e Farmacêutica S\u002FA","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":17,"sex":18,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":24,"phases":54,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":42},"100633635","evaluation-of-oral-collagen-peptides-on-skin-barrier-function-in-women-100633635","NCT07529249","Evaluation of Oral Collagen Peptides on Skin Barrier Function in Women","Evaluation of Oral Collagen Peptides on Skin Barrier Function in Women With Dry Skin","Inclusion Criteria:\n\n1. Participant having signed an Informed Consent Form (ICF);\n2. Healthy female Participant aged 45 to 70 years inclusive not followed by a healthcare practitioner for any skin disease;\n3. Participant with phototype II to IV according to the Fitzpatrick classification;\n4. Participant with dry skin measured on the cheeks (Tewameter, TEWL \\>15g\u002Fm²\u002Fh (skin barrier integrity) on back of the cheekbone)\n5. Female Participant of non-childbearing potential, defined as a woman without uterus and\u002For both ovaries, surgically sterile (at least 6 months prior to Screening visit) or post-menopausal (at least one year post cessation of menses);\n6. Female Participant of childbearing potential who has been using a highly effective birth control method for at least 1 month prior to Screening visit and agreeing to continue adequate contraception during the entire study period;\n\n   Highly effective birth control methods are:\n\n   \\- hormonal (combined or progestogen-only) contraception methods associated with inhibition of ovulation or intrauterine device; bilateral tubal occlusion since at least 3 months prior to Screening visit; vasectomised partner; True abstinence, i.e., refraining from heterosexual intercourse when this is in line with the preferred and usual lifestyle of the participant.\n7. Participant agreeing not to apply any cosmetic product (e.g. care cream, lotion, body milk) or drug on the face (except usual cleansing products) within 24 hours before the study visits;\n8. Participant agreeing to not apply cosmetic, medical, or aesthetic treatments out of the study protocol on the face and legs during the whole study duration;\n9. Participant affiliated to a health social security system (according to French Law).\n\nExclusion Criteria:\n\n1. Participant with a BMI ≤17 or ≥30 kg\u002Fcm²;\n2. Participant with any uncontrolled diseases such as diabetes, hypertension, hyperthyroidism or hypothyroidism;\n3. Presenting or having a history of eating disorder (e.g. anorexia, food allergy) or gastrointestinal malabsorption such as celiac disease, Crohn's disease, lactose intolerance;\n4. Participant with an history of sleeve or bypass;\n5. Participant currently participating in another clinical study or being in an exclusion period of another clinical study;\n6. Participant with known or suspected hypersensitivity to any component(s) of the investigational products or to any ingredients of the vehicles (i.e., excipients);\n7. Participant with a known allergy to beef-derived products;\n8. Participant who has used collagen supplements, vitamin C, or other skin related nutraceuticals within the last 3 months\n9. Participant who started using prescription medications to treat skin conditions or other medications that affect the skin during the three months prior to the study\n10. Participant who has made significant lifestyle changes in the past three months (altering their diet, starting new exercises, or changing their skincare routines)\n11. Participant with skin abnormalities (e.g., scars, excessive hair, tattooing) or any dermatosis (e.g., psoriasis, eczema, acne vulgaris) on the face and legs which could interfere with the study;\n12. Participant impossible to contact in case of emergency;\n13. Participant who, in the opinion of the investigator, is unlikely to comply with the Clinical Study Protocol (e.g., alcoholism, drug dependency or psychotic state);\n14. Participant who is in an exclusion period in the National Biomedical Research Register of the French Ministry of Health at randomization;\n15. Protected participant as defined in the Articles of the French Public Health Code. Article 1121-7: person deprived of liberty by a judicial or administrative decision, or participant to psychiatric care, or person admitted to a health or social institution for purposes other than the research. Article 1121-8: adult person participant to a legal protection measure or unable to express his\u002Fher consent. Article L3212-1: person undergoing compulsory psychiatric treatment. Article L3213-1: person having a mental disorder that requires care and that which may compromise the safety of third persons or seriously undermine public order;\n16. Participant unable to communicate or cooperate with the Investigator;\n17. Participant having received 6000 euros indemnities for participation in clinical trials\u002Finvestigations in the 12 previous months, including participation in the present study (according to French Law);","45 Years","70 Years",{"count":53,"type":23},75,[26],"This clinical study aims to determine whether taking two different doses of collagen-derived peptides for three months improves facial skin barrier integrity in women with dry, sensitive skin, compared with a placebo.",[57,29,58,59],"Dry Skin","Dry Skin in the Elderly","Dietary Supplement",[61,62,63,64,65],"cpcad","skinpharma","dry skin","dietary supplement","sensitive skin","2026-05-07",{"date":68,"type":34},"2026-05-12",{"date":70,"type":23},"2026-04",{"date":72,"type":23},"2026-09",{"name":74,"class":75},"Centre de Pharmacologie Clinique Applique a la Dermatologie","OTHER",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":17,"sex":18,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":24,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":42},"100598129","instant-flush-redness-clinical-efficacy-study-100598129","NCT07067476","Instant Flush Redness Clinical Efficacy Study","A Randomized, Double-Blind, Split-Face Clinical Study to Evaluate the Redness Relief Efficacy of Instant Flush Products in Subjects With Sensitive Skin","Inclusion Criteria:\n\n1. Chinese women aged from 20-40 years old.\n2. Self-declared mild sensitive skin.\n3. Self-declare with skin concerns of redness and easy to flush.\n4. Willing to be exposed to infrared light on the facial skin to induce facial redness(can tolerate heat sensation on the face).\n5. Clinical grading of skin redness (visual) ≥ 4 after infrared light induction (7-8 mins) by dermatologist.\n6. No disagreement of dermatologist because of other reasons that exclude the parficipation of the subject.\n7. In general good health at the time of the study.\n8. Willing and able to participate as evidenced by signing of informed consent and photo release\n\nExclusion Criteria:\n\n1. Allergic to infrared light\n2. Pregnant or breast-feeding woman or woman planning pregnancy during the study.\n3. Subject deprived of rights by a court or administrative order.\n4. Major subject to a guardianship order.\n5. Subject residing in a health or social care establishment.\n6. Patient in an emergency setting\n7. Subject with a skin disease in the test areas (particularly e.g, acne, rosacea, eczema).\n8. Subjects with history, of atopy, allergic reactions, irritation or intense discomfort feelings to topical-use products, medication, cosmetic: or personal care products or ingredients.\n9. Subject presenting a stable or progressive serious disease (per investigator's assessment).\n10. Immuno-compromised subject.\n11. Subject presenting excessive exposure to sunlight or UV radiation (investigator's assessment).\n12. Subjects regularly practicing aquatic or nautical sports.\n13. Subjects regularly attending a sauna.\n14. Subject with cardiovascular or circulatory history.\n15. Subject with a history of skin cancer or malignant melanoma.\n16. Intake of antihistamines, antibiotics, corticosteroids, non-steroidal anti-inflammatories or immune-suppressants in the last 6 months before study.","20 Years","40 Years",{"count":86,"type":23},60,[26],"The goal of this clinical trial is to learn if an anti-redness emulsion can help lower facial redness caused by heat in healthy adult women. The main questions it aims to answer are:\n\n* Does the anti-redness emulsion lower facial redness better than purified water?\n* Is the product safe and comfortable to use?\n\nResearchers will compare the anti-redness emulsion to purified water using a split-face method.\n\nParticipants will:\n\n* Receive infrared light on their face to trigger redness\n* Apply the anti-redness emulsion to one side of their face and purified water to the other side\n* Have their facial redness measured at different time points using photography, imaging devices, and skin redness tests\n* Answer questions about their experience with the products",[29],"NOT_YET_RECRUITING","2025-07-14",{"date":93,"type":34},"2025-07-16",{"date":95,"type":23},"2025-07-15",{"date":97,"type":23},"2025-10-31",{"name":99,"class":41},"ChinaNorm",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":17,"sex":107,"minAge":19,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":24,"phases":111,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":42},"100587561","a-clinical-study-to-assess-the-safety-and-effectiveness-of-test-product-in-healthy-adult-human-subjects-with-dry-or-sensitive-skin-100587561","NCT06929988","A Clinical Study to Assess the Safety and Effectiveness of Test Product in Healthy Adult Human Subjects With Dry or Sensitive Skin","A Clinical Safety, In-use Tolerability and Efficacy Study of the Test Product in Heathy Adult Human Subjects With Dry or Sensitive Skin","Inclusion Criteria:\n\n* Age: 18 to 55 years (both inclusive) at the time of consent.\n* Sex: Healthy male and non-pregnant\u002Fnon-lactating females.\n* Females of childbearing potential must have a self-reported negative pregnancy test.\n* Subject are generally in good health.\n* Subject with dry or sensitive skin at a time of screening. (Dermatological Assessment)\n* Subjects assessment site must be free of cuts, tattoos, scratches, abrasions, scars, uneven skin tone, sunburn, excessive tan, excessive hair or open wounds.\n* Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.\n* If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device\u002Finjection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.\n* Subjects are willing to give written informed consent and are willing to come for regular follow up.\n* Subjects who commit not to use medicated skincare products other than the test product for the entire duration of the study.\n* Subject who have not participated in a similar investigation in the past three months.\n* Willing to use test product throughout the study period.\n\nExclusion Criteria:\n\n* History of any dermatological condition of the skin diseases.\n* Subject with present condition of allergic response to any cosmetic product.\n* Subject having allergic response to the ink.\n* Presence of any broken, chapped, cut, irritated, or scraped skin at the application site.\n* Subjects under chronic medication (e.g. aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy etc.) that might influence the outcome of the study.\n* Subject having acne of severe incidence (presence of nodules, cysts or numerous pustules) which requires pharmaceutical or cosmeceuticals, herbal treatment.\n* Subjects who have applied topical treatment for at least 4 weeks and any systemic treatment for at least 3 months, before they participated in the study.\n* History of alcohol or drug addiction.\n* Subjects using other marketed products during the study period.\n* Any other condition which could warrant exclusion from the study, as per the dermatologist's\u002Finvestigator's discretion.\n* Pregnant or breastfeeding or planning to become pregnant during the study period.\n* History of chronic illness which may influence the cutaneous state.\n* Subjects participating in other similar cosmetics, devices or therapeutic trials or skincare products within the last four weeks.","ALL","55 Years",{"count":110,"type":23},32,[26],"This exploratory, prospective, open-label, single-centre, safety, efficacy and in-use tolerability study of the test product in healthy adult human subjects with dry or sensitive skin.",[57,29],"2025-04-19",{"date":116,"type":34},"2025-04-24",{"date":118,"type":23},"2025-05-15",{"date":120,"type":23},"2025-05-30",{"name":122,"class":75},"SAVA Healthcare Limited",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":107,"minAge":19,"maxAge":20,"enrollmentInfo":129,"targetDuration":4,"studyType":24,"phases":131,"briefSummary":127,"conditions":132,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":42},"100555811","the-application-of-bovine-basic-fibroblast-growth-factor-gel-in-the-treatment-of-sensitive-skin-100555811","NCT06516939","The Application of Bovine Basic Fibroblast Growth Factor Gel in the Treatment of Sensitive Skin","Inclusion Criteria:\n\n1. Sensitive skin with a diagnosis of persistent erythema and a lactate irritation test score of 2-3\n2. No related skin care products including bovine alkaline fibroblast growth factor were used within 1 month before participating in the experiment, and photoelectric treatment measures were not carried out\n3. Physical sunscreen should be strict during enrollment\n\nExclusion Criteria:\n\n1. Children\n2. Have serious heart, liver, kidney, and blood system diseases, and severe immunocompromise\n3. Patients with mental illness or cancer\n4. Those who have received glucocorticoids, calcineurin inhibitors, topical small molecule drugs, antibiotics or tretinoin within 3 months\n5. Those who are allergic to basic fibroblast growth factor gel and its components\n6. Acute dermatitis of the face and perifolliculitis",{"count":130,"type":23},28,[26],[29],"2024-07-23",{"date":135,"type":34},"2024-07-24",{"date":137,"type":34},"2024-06-10",{"date":139,"type":23},"2024-07-18",{"name":141,"class":75},"Shanghai Dermatology Hospital"]